‌

US Patent 10786523 Formulation comprising a gemcitabine-prodrug

Patent 10786523 was granted and assigned to NuCana on September, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

NuCana

Current Assignee

NuCana

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

107865230

Date of Patent

September 29, 2020

Patent Application Number

161429480

Date Filed

September 26, 2018

Patent Citations

‌

US Patent 10005810 Process for preparing nucleoside prodrugs

‌

US Patent 10117888 Formulation comprising a gemcitabine-prodrug

Patent Citations Received

‌

US Patent 11414452 Synthesis of phosphate derivatives

‌

US Patent 11629164 Gemcitabine prodrugs

‌

US Patent 11707477 Formulation comprising a gemcitabine-prodrug

‌

US Patent 11414451 Floxuridine synthesis

‌

US Patent 10906929 Phosphoramidate nucleoside derivatives as anticancer agents

‌

US Patent 11040051 Formulation comprising a gemcitabine-prodrug

Patent Primary Examiner

‌

Traviss C Mcintosh, III

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10786523 Formulation comprising a gemcitabine-prodrug

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API